NCT00500461View on ClinicalTrials.gov

Study To Examine Safety, Tolerability And Pharmacokinetics Of Intravenous Doses And Oral Dose Of GSK233705

PHASE1CompletedINTERVENTIONAL

Enrollment

9

Participants

Timeline

Start Date

June 4, 2007

Primary Completion Date

July 1, 2007

Study Completion Date

July 25, 2007

Conditions

Pulmonary Disease, Chronic Obstructive

Interventions

DRUG

GSK233705

GSK233705 will be available as IV infusion and oral solution containing Cellobiose octaacetate.

Trial Locations (1)

NW10 7NS

GSK Investigational Site, London

Sponsors

Lead Sponsor

GlaxoSmithKline

All Listed Sponsors

lead

GlaxoSmithKline

INDUSTRY